EXHIBIT 99.01
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | |
Press Release |
Basingstoke, UK and Philadelphia, US – February 25, 2008– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces that on 25 February 2008 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire plc Portfolio Share Plan (the “Plan”).
Awards of Stock Settled Appreciation Rights (“SARs”) under Part A of the Plan
Name of PDMR | Type of Security | No of Ordinary Shares or ADRs | Exercise price |
Angus Russell (Executive Director)* | Ordinary Share | 85,000 | £9.97 |
Michael Cola | ADR | 13,334 | $58.90 |
Sylvie Gregoire | ADR | 8,334 | $58.90 |
Tatjana May | Ordinary Share | 32,000 | £9.97 |
Barbara Deptula | ADR | 10,334 | $58.90 |
Joseph Rus | ADR | 10,000 | $58.90 |
Anita Graham | ADR | 10,000 | $58.90 |
*Awards to Executive Directors are subject to performance targets
SARs will normally vest after three years, subject to any performance targets. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.
Performance Share Awards (“PSP Awards”) under Part B of the Plan
Name of PDMR | Type of Security | No of Ordinary Shares or ADRs | Market value |
Angus Russell (Executive Director)* | Ordinary Share | 60,000 | £9.97 |
Michael Cola | ADR | 10,000 | $58.90 |
Sylvie Gregoire | ADR | 7,334 | $58.90 |
Tatjana May | Ordinary Share | 23,000 | £9.97 |
Barbara Deptula | ADR | 7,000 | $58.90 |
Joseph Rus | ADR | 6,667 | $58.90 |
Anita Graham | ADR | 6,667 | $58.90 |
*Awards to Executive Directors are subject to performance targets
The PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) pf the Disclosure Rules and Transparency Rules
T May
Company Secretary
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
Eric Rojas (North America) | +1 484 595 8252 | |
Media | Jessica Mann (Rest of the World) | +44 1256 894 280 |
Matthew Cabrey (North America) | +1 484 595 8248 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
Registered in England 2883758 Registered Office as above